Tetraphase Pharmaceuticals, Inc. (TTPH)

[rusty8350]

That $55 per share was when the outstanding shares was around 30 million. That gave a market cap value of 1.65 billion. The outstanding shares being higher and the fact that they're not going to initially have the cUTI indication or oral use of the drug will lead to a lower valuation no doubt, but high teens should still be easily manageable at that point. Big pharma could also seek a buyout - something I realistically believe could occur after approval. Pfizer would be a strong candidate IMO given the likely loss of revenue they would incur due to Eracacyclines approval.


Little material about biotech buyouts.... given approval of EU and FDA TTPH is going to be in a substantially higher position.

http://www.marketwatch.com/story/were-in-the-year-of-the-biotech-buyout-and-here-are-five-prime-targets-2017-01-23